Emergent Biosolutions (NYSE:EBS) Share Price Passes Above Two Hundred Day Moving Average – Here’s What Happened

Shares of Emergent Biosolutions Inc. (NYSE:EBS) crossed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $9.65 and traded as high as $12.58. Emergent Biosolutions shares last traded at $12.08, with a volume of 1,263,793 shares traded.

Analyst Ratings Changes

A number of research firms have issued reports on EBS. Wall Street Zen upgraded Emergent Biosolutions from a “buy” rating to a “strong-buy” rating in a research report on Sunday, November 30th. Zacks Research upgraded shares of Emergent Biosolutions to a “hold” rating in a research note on Friday, October 24th. HC Wainwright reiterated a “buy” rating and set a $15.00 price objective on shares of Emergent Biosolutions in a research report on Tuesday, December 16th. Finally, Weiss Ratings restated a “hold (c-)” rating on shares of Emergent Biosolutions in a research report on Monday, December 29th. One analyst has rated the stock with a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $15.00.

Emergent Biosolutions Trading Down 1.1%

The company has a current ratio of 5.76, a quick ratio of 3.15 and a debt-to-equity ratio of 1.14. The firm has a market capitalization of $627.77 million, a price-to-earnings ratio of 9.19 and a beta of 2.30. The firm’s 50-day moving average is $11.77 and its 200 day moving average is $9.69.

Emergent Biosolutions (NYSE:EBS) last announced its quarterly earnings results on Wednesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.12) by $1.18. The firm had revenue of $231.10 million during the quarter, compared to analysts’ expectations of $203.67 million. Emergent Biosolutions had a net margin of 9.62% and a return on equity of 20.85%. On average, equities analysts predict that Emergent Biosolutions Inc. will post -0.63 earnings per share for the current fiscal year.

Insider Activity

In related news, Director Ronald Richard sold 21,984 shares of Emergent Biosolutions stock in a transaction that occurred on Friday, December 5th. The stock was sold at an average price of $11.97, for a total value of $263,148.48. Following the transaction, the director directly owned 98,417 shares of the company’s stock, valued at $1,178,051.49. The trade was a 18.26% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 1.20% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in EBS. Assenagon Asset Management S.A. boosted its stake in shares of Emergent Biosolutions by 2.4% in the 4th quarter. Assenagon Asset Management S.A. now owns 57,805 shares of the biopharmaceutical company’s stock valued at $714,000 after purchasing an additional 1,350 shares during the last quarter. Wealth Enhancement Advisory Services LLC lifted its holdings in Emergent Biosolutions by 14.3% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 13,016 shares of the biopharmaceutical company’s stock valued at $171,000 after buying an additional 1,625 shares during the period. Vanguard Personalized Indexing Management LLC boosted its position in Emergent Biosolutions by 14.1% during the second quarter. Vanguard Personalized Indexing Management LLC now owns 17,824 shares of the biopharmaceutical company’s stock valued at $114,000 after acquiring an additional 2,204 shares during the last quarter. Cetera Investment Advisers boosted its position in Emergent Biosolutions by 0.7% during the second quarter. Cetera Investment Advisers now owns 358,952 shares of the biopharmaceutical company’s stock valued at $2,290,000 after acquiring an additional 2,671 shares during the last quarter. Finally, Profund Advisors LLC grew its holdings in Emergent Biosolutions by 23.9% during the 3rd quarter. Profund Advisors LLC now owns 20,425 shares of the biopharmaceutical company’s stock worth $180,000 after acquiring an additional 3,937 shares during the period. Institutional investors own 78.40% of the company’s stock.

About Emergent Biosolutions

Emergent BioSolutions is a global specialty biopharmaceutical company focused on developing, manufacturing and commercializing medical countermeasures and specialty products that address public health threats. The company’s portfolio includes vaccines, antibody therapies and critical care products designed to protect against biological, chemical and emerging infectious disease threats. Emergent has longstanding partnerships with government agencies, including the U.S. Department of Defense and the Biomedical Advanced Research and Development Authority (BARDA), to support national preparedness programs.

Key commercial products in Emergent’s lineup include BioThrax (anthrax vaccine adsorbed), ACAM2000 (smallpox vaccine) and Vaxchora (cholera vaccine), alongside therapeutic treatments such as Anthrasil (anthrax immune globulin) and the naloxone-based nasal spray Narcan for opioid overdose reversal.